Literature DB >> 18362146

A composite role of vitronectin and urokinase in the modulation of cell morphology upon expression of the urokinase receptor.

Thore Hillig1, Lars H Engelholm, Signe Ingvarsen, Daniel H Madsen, Henrik Gårdsvoll, Jørgen K Larsen, Michael Ploug, Keld Danø, Lars Kjøller, Niels Behrendt.   

Abstract

The urokinase receptor, urokinase receptor (uPAR), is a glycosylphosphatidylinositol-anchored membrane protein engaged in pericellular proteolysis and cellular adhesion, migration, and modulation of cell morphology. A direct matrix adhesion is mediated through the binding of uPAR to vitronectin, and this event is followed by downstream effects including changes in the cytoskeletal organization. However, it remains unclear whether the adhesion through uPAR-vitronectin is the only event capable of initiating these morphological rearrangements or whether lateral interactions between uPAR and integrins can induce the same response. In this report, we show that both of these triggering mechanisms can be operative and that uPAR-dependent modulation of cell morphology can indeed occur independently of a direct vitronectin binding. Expression of wild-type uPAR on HEK293 cells led to pronounced vitronectin adhesion and cytoskeletal rearrangements, whereas a mutant uPAR, uPAR(W32A) with defective vitronectin binding, failed to induce both phenomena. However, upon saturation of uPAR(W32A) with the protease ligand, pro-uPA, or its receptor-binding domain, the ability to induce cytoskeletal rearrangements was restored, although this did not rescue the uPAR-vitronectin binding and adhesion capability. On the other hand, using other uPAR variants, we could show that uPAR-vitronectin adhesion is indeed capable and sufficient to induce the same morphological rearrangements. This was shown with cells expressing a different single-site mutant, uPAR(Y57A), in the presence of a synthetic uPAR-binding peptide, as well as with wild-type uPAR, which underwent cytoskeletal rearrangements even when cultivated in uPA-deficient serum. Blocking of integrins with an Arg-Gly-Asp-containing peptide counteracted the matrix contacts necessary to initiate the uPAR-dependent cytoskeletal rearrangements, whereas inactivation of the Rac signaling pathway in all cases suppressed the occurrence of the same events.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18362146      PMCID: PMC3258879          DOI: 10.1074/jbc.C700214200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  39 in total

1.  Structure of human urokinase plasminogen activator in complex with its receptor.

Authors:  Qing Huai; Andrew P Mazar; Alice Kuo; Graham C Parry; David E Shaw; Jennifer Callahan; Yongdong Li; Cai Yuan; Chuanbing Bian; Liqing Chen; Bruce Furie; Barbara C Furie; Douglas B Cines; Mingdong Huang
Journal:  Science       Date:  2006-02-03       Impact factor: 47.728

Review 2.  Does the urokinase receptor exist in a latent form?

Authors:  C Yuan; M Huang
Journal:  Cell Mol Life Sci       Date:  2007-05       Impact factor: 9.261

Review 3.  Plasminogen activation and cancer.

Authors:  Keld Danø; Niels Behrendt; Gunilla Høyer-Hansen; Morten Johnsen; Leif R Lund; Michael Ploug; John Rømer
Journal:  Thromb Haemost       Date:  2005-04       Impact factor: 5.249

4.  Plasminogen activation independent of uPA and tPA maintains wound healing in gene-deficient mice.

Authors:  Leif R Lund; Kirsty A Green; Allart A Stoop; Michael Ploug; Kasper Almholt; Jennifer Lilla; Boye S Nielsen; Ib J Christensen; Charles S Craik; Zena Werb; Keld Danø; John Rømer
Journal:  EMBO J       Date:  2006-06-08       Impact factor: 11.598

5.  Mapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region.

Authors:  Henrik Gårdsvoll; Michael Ploug
Journal:  J Biol Chem       Date:  2007-03-13       Impact factor: 5.157

6.  Characterization of the functional epitope on the urokinase receptor. Complete alanine scanning mutagenesis supplemented by chemical cross-linking.

Authors:  Henrik Gårdsvoll; Bernard Gilquin; Marie Hélène Le Du; Andre Ménèz; Thomas J D Jørgensen; Michael Ploug
Journal:  J Biol Chem       Date:  2006-05-03       Impact factor: 5.157

7.  Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor.

Authors:  Boye S Nielsen; Fritz Rank; Martin Illemann; Leif R Lund; Keld Danø
Journal:  Int J Cancer       Date:  2007-05-15       Impact factor: 7.396

8.  A region in urokinase plasminogen receptor domain III controlling a functional association with alpha5beta1 integrin and tumor growth.

Authors:  Pratima Chaurasia; Julio A Aguirre-Ghiso; Olin D Liang; Henrik Gardsvoll; Michael Ploug; Liliana Ossowski
Journal:  J Biol Chem       Date:  2006-03-17       Impact factor: 5.157

9.  Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling.

Authors:  J A Aguirre Ghiso; K Kovalski; L Ossowski
Journal:  J Cell Biol       Date:  1999-10-04       Impact factor: 10.539

10.  uPAR-induced cell adhesion and migration: vitronectin provides the key.

Authors:  Chris D Madsen; Gian Maria Sarra Ferraris; Annapaola Andolfo; Orla Cunningham; Nicolai Sidenius
Journal:  J Cell Biol       Date:  2007-06-04       Impact factor: 10.539

View more
  14 in total

1.  Urinary-type plasminogen activator receptor (uPAR) modulates oral cancer cell behavior with alteration in p130cas.

Authors:  Zonggao Shi; Yueying Liu; Jeffrey J Johnson; M Sharon Stack
Journal:  Mol Cell Biochem       Date:  2011-06-01       Impact factor: 3.396

2.  Vitronectin and Urokinase-Type Plasminogen Activator Gene Expression Levels Are Increased in Patients with Coronary Artery In-Stent Restenosis.

Authors:  S M Shafiee; F Noorabad-Ghahroodi; A Amirfarhangi; S R Hosseini-Fard; Z Sharifi; M Najafi
Journal:  Int J Angiol       Date:  2017-04-16

3.  The non-phagocytic route of collagen uptake: a distinct degradation pathway.

Authors:  Daniel H Madsen; Signe Ingvarsen; Henrik J Jürgensen; Maria C Melander; Lars Kjøller; Amanda Moyer; Christian Honoré; Charlotte A Madsen; Peter Garred; Sven Burgdorf; Thomas H Bugge; Niels Behrendt; Lars H Engelholm
Journal:  J Biol Chem       Date:  2011-06-07       Impact factor: 5.157

Review 4.  Regulation of cell signalling by uPAR.

Authors:  Harvey W Smith; Chris J Marshall
Journal:  Nat Rev Mol Cell Biol       Date:  2010-01       Impact factor: 94.444

5.  Urokinase-type plasminogen activator inhibits efferocytosis of neutrophils.

Authors:  Yanping Yang; Arnaud Friggeri; Sami Banerjee; Khalil Bdeir; Douglas B Cines; Gang Liu; Edward Abraham
Journal:  Am J Respir Crit Care Med       Date:  2010-07-23       Impact factor: 21.405

6.  Conformational regulation of urokinase receptor function: impact of receptor occupancy and epitope-mapped monoclonal antibodies on lamellipodia induction.

Authors:  Henrik Gårdsvoll; Benedikte Jacobsen; Mette C Kriegbaum; Niels Behrendt; Lars Engelholm; Søren Østergaard; Michael Ploug
Journal:  J Biol Chem       Date:  2011-07-28       Impact factor: 5.157

7.  Serum-stable RNA aptamers to urokinase-type plasminogen activator blocking receptor binding.

Authors:  Daniel Miotto Dupont; Jeppe Buur Madsen; Roland Karl Hartmann; Bertrand Tavitian; Frédéric Ducongé; Jørgen Kjems; Peter André Andreasen
Journal:  RNA       Date:  2010-10-20       Impact factor: 4.942

8.  Mimicry of the regulatory role of urokinase in lamellipodia formation by introduction of a non-native interdomain disulfide bond in its receptor.

Authors:  Henrik Gårdsvoll; Magnus Kjaergaard; Benedikte Jacobsen; Mette C Kriegbaum; Mingdong Huang; Michael Ploug
Journal:  J Biol Chem       Date:  2011-10-24       Impact factor: 5.157

9.  A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.

Authors:  Degang Liu; Donghui Zhou; Bo Wang; William Eric Knabe; Samy O Meroueh
Journal:  ACS Chem Biol       Date:  2015-03-31       Impact factor: 5.100

10.  Vitronectin inhibits efferocytosis through interactions with apoptotic cells as well as with macrophages.

Authors:  Hong-Beom Bae; Jean-Marc Tadie; Shaoning Jiang; Dae Won Park; Celeste P Bell; Lawrence C Thompson; Cynthia B Peterson; Victor J Thannickal; Edward Abraham; Jaroslaw W Zmijewski
Journal:  J Immunol       Date:  2013-01-23       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.